SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-007582
Filing Date
2024-01-30
Accepted
2024-01-30 08:02:36
Documents
16
Period of Report
2024-01-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192396-8k_inmune.htm   iXBRL 8-K 24237
2 PRESS RELEASE DATED JANUARY 30, 2024 ea192396ex99-1_inmune.htm EX-99.1 9964
6 GRAPHIC ex99-1_001.jpg GRAPHIC 1870
  Complete submission text file 0001213900-24-007582.txt   215053

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE inmb-20240130.xsd EX-101.SCH 3018
4 XBRL LABEL FILE inmb-20240130_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE inmb-20240130_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea192396-8k_inmune_htm.xml XML 3721
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

IRS No.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 24575910
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)